Selexipag improves outcomes in PAH-associated connective tissue disease in real-world study
SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease.At the American Thoracic Society International Conference, Sean Gaine, MD, with the National Pulmonary Hypertension Unit at Mater Misericordiae Hospital in Dublin, Ireland, and colleagues reported patient